Perspective Therapeutics, Inc. (CATX)

Market Cap	289.49M
Revenue (ttm)	1.47M
Net Income (ttm)	-85.17M
Shares Out	74.23M
EPS (ttm)	-1.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,704,626
Open	3.960
Previous Close	4.000
Day's Range	3.750 - 4.188
52-Week Range	1.600 - 16.550
Beta	1.19
Analysts	Strong Buy
Price Target	12.90 (+228.24%)
Earnings Date	Aug 13, 2025

About CATX

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-α-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 140
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CATX

Financial Performance

In 2024, Perspective Therapeutics's revenue was $1.45 million, an increase of 1.39% compared to the previous year's $1.43 million. Losses were -$79.28 million, 70.5% more than in 2023.

Analyst Summary

According to 11 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price target is $12.9, which is an increase of 228.24% from the latest price.

Price Target

$12.9

(228.24% upside)

Analyst Consensus: Strong Buy